A Phase 2 interventional study of Investigational new drug, company code: BGG492 and Placebo in Partial Onset Seizures, sponsored by Novartis. Completed at 51 sites in 10 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will assess the efficacy and safety of BGG492 as adjunctive treatment in patients with partial onset seizures.
758 studies on the registry are indexed under Nervous System Diseases; 217 are open to participants now.
This study's enrollment of 93 is above the median of 55 across 496 interventional studies indexed under Nervous System Diseases.
Browse Nervous System Diseases studies →Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Drug: Investigational new drug, company code: BGG492
Drug: Placebo
Drug: Investigational new drug, company code: BGG492
Drug pages: Drugs, Investigational · Selurampanel
Drug pages: Drugs, Investigational · Selurampanel
To detect a dose-response by measuring the percent change in seizure frequency of BGG492 from baseline to maintenance period.
Time frame: 28 days
To evaluate the efficacy of BGG492 compared to placebo as a change in seizure frequency from baseline period to maintenance period.
Time frame: 28 days
Responder rate: analysis of patients with a 50% or greater reduction in seizure frequency of BGG492 during the maintenance period.
Time frame: 28 days
Safety and tolerability of BGG492 compared to placebo.
Time frame: 12 weeks
Pharmacokinetic profile of BGG492
Time frame: 10 weeks
The record gives a start of Jun 2010, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Drugs, Investigational · Selurampanel